Safety study of ZT002 injection in overweight adults
Part of Hormones & metabolism clinical trials.
This study tests how a new diabetes medicine called ZT002 works in the body and whether it interacts safely with other common medications. Researchers will monitor healthy volunteers who are overweight to understand the medicine's safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–45 years old
- Overweight or obese (BMI 24–35 kg/m²) with minimum body weight (males >60 kg, females >55 kg)
- Generally healthy with normal heart function, blood work, and no serious medical conditions in the past 6 months
- No history of thyroid cancer, pancreas problems, gallstones, or blood sugar issues
- No diabetes medications, blood thinners, or other prescription drugs in the past 2–3 weeks
- Normal thyroid and liver function tests, plus normal blood sugar and calcitonin levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a new medication called Zovaglutide affects the heart's electrical activity (QTc interval) in healthy adults. It helps ensure the drug is safe before moving to larger trials.
This study tests an investigational drug called Zovaglutide (ZT002) in people with different levels of kidney function, from normal to severely impaired. The goal is to see how the drug is processed by the body and how safe it is for people with kidney problems.
This trial tests an investigational injection called ZT003 to see if it is safe and how the body processes it. It is for healthy volunteers or those who are overweight or obese, to help understand how this treatment might work.
This study tests how a new injectable weight loss drug affects the way the body processes metformin, a common diabetes medication. It is for Chinese adults who are overweight or obese.
This trial tests a new injection (GZR102) compared to two other injections (GZR4 and GZR18) in overweight adults. The goal is to see how well the body processes each drug and their effects. It may help researchers find a better treatment for weight management.
This study tests whether a change in the manufacturing process for GZR18 (an experimental injectable drug) affects how it works in the body. It may help determine if the new version is as safe and effective as the original.
Hear when a new Overweight,Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.